Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Beam Therapeutics Inc is a biotechnology business based in the US. Beam Therapeutics Inc shares (BEAM) are listed on the NASDAQ and all prices are listed in US Dollars. Beam Therapeutics Inc employs 394 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $39.79 |
|---|---|
| 52-week range | $27.77 - $129.50 |
| 50-day moving average | $36.72 |
| 200-day moving average | $65.47 |
| Wall St. target price | $89.55 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.59 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $39.79 from 2022-07-01
| 1 week (2022-06-28) | -1.51% |
|---|---|
| 1 month (2022-06-01) | 16.93% |
| 3 months (2022-04-05) | -29.51% |
| 6 months (2022-01-01) | N/A |
| 1 year (2021-07-02) | -69.44% |
|---|---|
| 2 years (2020-07-02) | 37.82% |
| 3 years (2019-07-01) | N/A |
| 5 years (2017-07-01) | N/A |
| Revenue TTM | $60.3 million |
|---|---|
| Gross profit TTM | $-180,290,000 |
| Return on assets TTM | -6.6% |
| Return on equity TTM | -38.08% |
| Profit margin | 0% |
| Book value | $12.16 |
| Market capitalisation | $2.8 billion |
TTM: trailing 12 months
We're not expecting Beam Therapeutics Inc to pay a dividend over the next 12 months.
Over the last 12 months, Beam Therapeutics Inc's shares have ranged in value from as little as $27.77 up to $129.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Beam Therapeutics Inc's is 1.6025. This would suggest that Beam Therapeutics Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Beam Therapeutics Inc. , a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc. ; license agreement with Sana Biotechnology, Inc. ; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.